Cargando…

Genetic determinants of cocaine-associated agranulocytosis

BACKGROUND: Drug-induced agranulocytosis is a recognized adverse drug event associated with serious infectious complications. Levamisole is an antihelminthic and immunomodulator withdrawn from North American markets in 2005 after reports of agranulocytosis. Previous studies of levamisole, suggest th...

Descripción completa

Detalles Bibliográficos
Autores principales: Buxton, Jane A, Omura, John, Kuo, Margot, Ross, Colin, Tzemis, Despina, Purssell, Roy, Gardy, Jennifer, Carleton, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467676/
https://www.ncbi.nlm.nih.gov/pubmed/26070312
http://dx.doi.org/10.1186/s13104-015-1219-4
_version_ 1782376401368776704
author Buxton, Jane A
Omura, John
Kuo, Margot
Ross, Colin
Tzemis, Despina
Purssell, Roy
Gardy, Jennifer
Carleton, Bruce
author_facet Buxton, Jane A
Omura, John
Kuo, Margot
Ross, Colin
Tzemis, Despina
Purssell, Roy
Gardy, Jennifer
Carleton, Bruce
author_sort Buxton, Jane A
collection PubMed
description BACKGROUND: Drug-induced agranulocytosis is a recognized adverse drug event associated with serious infectious complications. Levamisole is an antihelminthic and immunomodulator withdrawn from North American markets in 2005 after reports of agranulocytosis. Previous studies of levamisole, suggest that the human leukocyte antigen (HLA)-B27 confers a genetic predisposition to this adverse drug event. Since 2009, emergency room visits due to agranulocytosis in individuals consuming levamisole-adulterated crack-cocaine have increased. METHODS: We performed a case–control study using a genotyping assay and novel gene chip to test the association between cocaine-associated agranulocytosis (CAA) and HLA-B27 and to identify pharmacokinetic and pharmacodynamic gene variants associated with the phenotype. RESULTS: Fifty-one CAA cases were identified through a provincial physician reporting system between 2008 and 2011. We examined eight of these cases and 26 matched controls. Genotyping revealed a significant association between HLA-B27 and CAA (odds ratio [OR] 9.2, 95% confidence interval [CI], 1.54–54.6). We also observed a similar association with the HLA-B27 tag single nucleotide polymorphism rs4349859 (OR 9.2, 95% CI 1.5–54.6) and rs13202464 (OR 6.7, 95% CI 1.1–41). Further associations were identified with variants in the ARBCC12 (OR 10.0, 95% CI 2.7–36.8) and CYP11A1 (OR 7.4, 95% CI 2.1–26.6) genes, while a novel protective association was observed with variants in the ARDB1 gene (OR 0.06, 95% CI 0.007–0.46). CONCLUSIONS: We confirmed the association of HLA-B27 with CAA and identified additional susceptibility variants. Health care providers should inform people who are identified as having CAA that it is genetically determined and can recur with continued cocaine use. The severity of infections and subsequent hospitalization, and the risk of recurrence may prompt health-promoting behaviour changes of the affected individuals. These genetic associations warrant the attention of public health and knowledge translation efforts to highlight the implications for susceptibility to this severe adverse drug event.
format Online
Article
Text
id pubmed-4467676
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44676762015-06-16 Genetic determinants of cocaine-associated agranulocytosis Buxton, Jane A Omura, John Kuo, Margot Ross, Colin Tzemis, Despina Purssell, Roy Gardy, Jennifer Carleton, Bruce BMC Res Notes Research Article BACKGROUND: Drug-induced agranulocytosis is a recognized adverse drug event associated with serious infectious complications. Levamisole is an antihelminthic and immunomodulator withdrawn from North American markets in 2005 after reports of agranulocytosis. Previous studies of levamisole, suggest that the human leukocyte antigen (HLA)-B27 confers a genetic predisposition to this adverse drug event. Since 2009, emergency room visits due to agranulocytosis in individuals consuming levamisole-adulterated crack-cocaine have increased. METHODS: We performed a case–control study using a genotyping assay and novel gene chip to test the association between cocaine-associated agranulocytosis (CAA) and HLA-B27 and to identify pharmacokinetic and pharmacodynamic gene variants associated with the phenotype. RESULTS: Fifty-one CAA cases were identified through a provincial physician reporting system between 2008 and 2011. We examined eight of these cases and 26 matched controls. Genotyping revealed a significant association between HLA-B27 and CAA (odds ratio [OR] 9.2, 95% confidence interval [CI], 1.54–54.6). We also observed a similar association with the HLA-B27 tag single nucleotide polymorphism rs4349859 (OR 9.2, 95% CI 1.5–54.6) and rs13202464 (OR 6.7, 95% CI 1.1–41). Further associations were identified with variants in the ARBCC12 (OR 10.0, 95% CI 2.7–36.8) and CYP11A1 (OR 7.4, 95% CI 2.1–26.6) genes, while a novel protective association was observed with variants in the ARDB1 gene (OR 0.06, 95% CI 0.007–0.46). CONCLUSIONS: We confirmed the association of HLA-B27 with CAA and identified additional susceptibility variants. Health care providers should inform people who are identified as having CAA that it is genetically determined and can recur with continued cocaine use. The severity of infections and subsequent hospitalization, and the risk of recurrence may prompt health-promoting behaviour changes of the affected individuals. These genetic associations warrant the attention of public health and knowledge translation efforts to highlight the implications for susceptibility to this severe adverse drug event. BioMed Central 2015-06-13 /pmc/articles/PMC4467676/ /pubmed/26070312 http://dx.doi.org/10.1186/s13104-015-1219-4 Text en © Buxton et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Buxton, Jane A
Omura, John
Kuo, Margot
Ross, Colin
Tzemis, Despina
Purssell, Roy
Gardy, Jennifer
Carleton, Bruce
Genetic determinants of cocaine-associated agranulocytosis
title Genetic determinants of cocaine-associated agranulocytosis
title_full Genetic determinants of cocaine-associated agranulocytosis
title_fullStr Genetic determinants of cocaine-associated agranulocytosis
title_full_unstemmed Genetic determinants of cocaine-associated agranulocytosis
title_short Genetic determinants of cocaine-associated agranulocytosis
title_sort genetic determinants of cocaine-associated agranulocytosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467676/
https://www.ncbi.nlm.nih.gov/pubmed/26070312
http://dx.doi.org/10.1186/s13104-015-1219-4
work_keys_str_mv AT buxtonjanea geneticdeterminantsofcocaineassociatedagranulocytosis
AT omurajohn geneticdeterminantsofcocaineassociatedagranulocytosis
AT kuomargot geneticdeterminantsofcocaineassociatedagranulocytosis
AT rosscolin geneticdeterminantsofcocaineassociatedagranulocytosis
AT tzemisdespina geneticdeterminantsofcocaineassociatedagranulocytosis
AT purssellroy geneticdeterminantsofcocaineassociatedagranulocytosis
AT gardyjennifer geneticdeterminantsofcocaineassociatedagranulocytosis
AT carletonbruce geneticdeterminantsofcocaineassociatedagranulocytosis